Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Radius Health's Enterprise Value is $747.9 Mil.
Radius Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 was $-49.9 Mil. Therefore, Radius Health's EV-to-EBIT ratio for today is -14.99.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Radius Health's Enterprise Value is $747.9 Mil.
Radius Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $-48.5 Mil. Therefore, Radius Health's EV-to-EBITDA ratio for today is -15.44.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Radius Health's Enterprise Value is $747.9 Mil.
Radius Health's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 was $223.4 Mil. Therefore, Radius Health's EV-to-Revenue ratio for today is 3.35.
Radius Health Enterprise Value Historical Data
The historical data trend for Radius Health's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Radius Health's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Radius Health's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radius Health's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Radius Health's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Radius Health's Enterprise Value falls into.
Radius Health Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Radius Health's Enterprise Value for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radius Health (NAS:RDUS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Radius Health's current Enterprise Value is $747.9 Mil.
Radius Health's EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-49.9 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Radius Health's current Enterprise Value is $747.9 Mil.
Radius Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-48.5 Mil.
Radius Health's current Enterprise Value is $747.9 Mil.
Radius Health's Revenue for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $223.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radius Health Enterprise Value Related Terms
Thank you for viewing the detailed overview of Radius Health's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Radius Health (Radius Health) Business Description
Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140. It primarily operates the business in the United States of America and generates key revenue from the sales of TYMLOS.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RDUS has been successfully added to your 